New quadrivalent flu mist vaccine for children, adults

Article

The first influenza vaccine to contain 2 strains of influenza A virus and 2 strains of influenza B has been approved by the US Food and Drug Administration for use in healthy children aged 2 years and older and adults to age 49 years.

The first influenza vaccine to contain 2 strains of influenza A virus and 2 strains of influenza B has been approved by the US Food and Drug Administration for use in healthy children aged 2 years and older and adults to age 49 years.

The new quadrivalent intranasal vaccine contains weakened forms of the live influenza viruses and is administered as a spray into the nose. The addition of the second influenza B strain increases a person's overall protection against seasonal influenza infection.

Three clinical studies involving 4,000 children and adults were conducted for safety and effectiveness of the quadrivalent vaccine and demonstrated that immune responses were similar between the new formulation and the older trivalent intranasal vaccine previously approved for children and adults.

The Centers for Disease Control and Prevention recommends that all persons aged 6 months and older be vaccinated annually against seasonal influenza. Attenuated intranasal influenza vaccine should not be administered to children younger than 2 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.